JPWO2019234690A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019234690A5 JPWO2019234690A5 JP2020567972A JP2020567972A JPWO2019234690A5 JP WO2019234690 A5 JPWO2019234690 A5 JP WO2019234690A5 JP 2020567972 A JP2020567972 A JP 2020567972A JP 2020567972 A JP2020567972 A JP 2020567972A JP WO2019234690 A5 JPWO2019234690 A5 JP WO2019234690A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- phenyl
- dione
- methyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 72
- 208000011580 syndromic disease Diseases 0.000 claims description 62
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 55
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 55
- 230000007812 deficiency Effects 0.000 claims description 40
- 208000035475 disorder Diseases 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 39
- 201000010099 disease Diseases 0.000 claims description 36
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 32
- OXVFDZYQLGRLCD-UHFFFAOYSA-N hydroxypioglitazone Chemical compound N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-UHFFFAOYSA-N 0.000 claims description 32
- 208000012268 mitochondrial disease Diseases 0.000 claims description 32
- 239000002552 dosage form Substances 0.000 claims description 31
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 25
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 23
- 239000000090 biomarker Substances 0.000 claims description 22
- 108010016731 PPAR gamma Proteins 0.000 claims description 21
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 21
- JMLKLMFMQRAJNI-UHFFFAOYSA-N 5-[[4-[2-(5-acetylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC(C(=O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 JMLKLMFMQRAJNI-UHFFFAOYSA-N 0.000 claims description 20
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 20
- 201000006938 muscular dystrophy Diseases 0.000 claims description 20
- 239000006186 oral dosage form Substances 0.000 claims description 19
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 16
- 206010033799 Paralysis Diseases 0.000 claims description 16
- 206010015037 epilepsy Diseases 0.000 claims description 16
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 16
- 208000021090 palsy Diseases 0.000 claims description 16
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 16
- 208000015114 central nervous system disease Diseases 0.000 claims description 15
- 230000001684 chronic effect Effects 0.000 claims description 15
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 14
- 206010003591 Ataxia Diseases 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 14
- 230000002757 inflammatory effect Effects 0.000 claims description 13
- 230000036470 plasma concentration Effects 0.000 claims description 13
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 12
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 12
- 208000012902 Nervous system disease Diseases 0.000 claims description 12
- 208000006011 Stroke Diseases 0.000 claims description 12
- 208000006443 lactic acidosis Diseases 0.000 claims description 12
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 12
- 208000005264 motor neuron disease Diseases 0.000 claims description 12
- 201000001119 neuropathy Diseases 0.000 claims description 12
- 230000007823 neuropathy Effects 0.000 claims description 12
- 230000000750 progressive effect Effects 0.000 claims description 12
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 12
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 11
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 10
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000004770 neurodegeneration Effects 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 8
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 claims description 8
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 claims description 8
- 206010058892 Carnitine deficiency Diseases 0.000 claims description 8
- 208000007514 Herpes zoster Diseases 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 8
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 claims description 8
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 claims description 8
- 208000013234 Pearson syndrome Diseases 0.000 claims description 8
- 201000007737 Retinal degeneration Diseases 0.000 claims description 8
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 208000029560 autism spectrum disease Diseases 0.000 claims description 8
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 8
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000003412 degenerative effect Effects 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000008774 maternal effect Effects 0.000 claims description 8
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 8
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 claims description 8
- 201000011548 mitochondrial DNA depletion syndrome 4b Diseases 0.000 claims description 8
- 230000002438 mitochondrial effect Effects 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 210000001328 optic nerve Anatomy 0.000 claims description 8
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 206010018691 Granuloma Diseases 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 7
- 208000033866 Rare inborn errors of metabolism Diseases 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 7
- 208000023504 respiratory system disease Diseases 0.000 claims description 7
- 208000017520 skin disease Diseases 0.000 claims description 7
- 210000001685 thyroid gland Anatomy 0.000 claims description 7
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 6
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 6
- 201000009906 Meningitis Diseases 0.000 claims description 6
- 208000026072 Motor neurone disease Diseases 0.000 claims description 6
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 6
- 201000010901 lateral sclerosis Diseases 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 5
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 5
- 201000002568 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- KDZOASGQNOPSCU-WDSKDSINSA-N Argininosuccinic acid Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)N[C@H](C(O)=O)CC(O)=O KDZOASGQNOPSCU-WDSKDSINSA-N 0.000 claims description 4
- 208000004724 Ataxia neuropathy spectrum Diseases 0.000 claims description 4
- 206010003694 Atrophy Diseases 0.000 claims description 4
- 201000006474 Brain Ischemia Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000014644 Brain disease Diseases 0.000 claims description 4
- 206010063292 Brain stem syndrome Diseases 0.000 claims description 4
- XIMFMKVTEVETRX-UHFFFAOYSA-N CC(=O)C1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3.Cl Chemical compound CC(=O)C1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3.Cl XIMFMKVTEVETRX-UHFFFAOYSA-N 0.000 claims description 4
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 claims description 4
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 claims description 4
- 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 claims description 4
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 4
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 206010010904 Convulsion Diseases 0.000 claims description 4
- 102100028675 DNA polymerase subunit gamma-2, mitochondrial Human genes 0.000 claims description 4
- 206010011878 Deafness Diseases 0.000 claims description 4
- 206010011891 Deafness neurosensory Diseases 0.000 claims description 4
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- 208000010772 Dog disease Diseases 0.000 claims description 4
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 4
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 4
- 208000032274 Encephalopathy Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 4
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims description 4
- 101000837415 Homo sapiens DNA polymerase subunit gamma-2, mitochondrial Proteins 0.000 claims description 4
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 4
- 208000025121 Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome Diseases 0.000 claims description 4
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims description 4
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims description 4
- 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims description 4
- 208000005446 Lupus vulgaris Diseases 0.000 claims description 4
- 201000005505 Measles Diseases 0.000 claims description 4
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 206010028289 Muscle atrophy Diseases 0.000 claims description 4
- 208000021642 Muscular disease Diseases 0.000 claims description 4
- 208000003926 Myelitis Diseases 0.000 claims description 4
- 201000009623 Myopathy Diseases 0.000 claims description 4
- 201000002481 Myositis Diseases 0.000 claims description 4
- 208000010316 Myotonia congenita Diseases 0.000 claims description 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
- 206010029323 Neuromyopathy Diseases 0.000 claims description 4
- 102100035196 POLG alternative reading frame Human genes 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000008425 Protein deficiency Diseases 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 4
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims description 4
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims description 4
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims description 4
- 208000012658 Skin autoimmune disease Diseases 0.000 claims description 4
- 208000029033 Spinal Cord disease Diseases 0.000 claims description 4
- 102000046669 Surf-1 Human genes 0.000 claims description 4
- 108060007963 Surf-1 Proteins 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 208000012130 acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- 230000037444 atrophy Effects 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 210000000133 brain stem Anatomy 0.000 claims description 4
- 239000003610 charcoal Substances 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 201000011474 congenital myopathy Diseases 0.000 claims description 4
- 229940109239 creatinine Drugs 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 206010014599 encephalitis Diseases 0.000 claims description 4
- 230000001815 facial effect Effects 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 230000009395 genetic defect Effects 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000010370 hearing loss Effects 0.000 claims description 4
- 231100000888 hearing loss Toxicity 0.000 claims description 4
- 208000016354 hearing loss disease Diseases 0.000 claims description 4
- 230000001771 impaired effect Effects 0.000 claims description 4
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 231100000518 lethal Toxicity 0.000 claims description 4
- 230000001665 lethal effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000020763 muscle atrophy Effects 0.000 claims description 4
- 201000000585 muscular atrophy Diseases 0.000 claims description 4
- 230000003274 myotonic effect Effects 0.000 claims description 4
- 208000018360 neuromuscular disease Diseases 0.000 claims description 4
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 230000010627 oxidative phosphorylation Effects 0.000 claims description 4
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000006825 purine synthesis Effects 0.000 claims description 4
- 230000006824 pyrimidine synthesis Effects 0.000 claims description 4
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 claims description 4
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 4
- 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- JHLDJOBIUVJSTG-UHFFFAOYSA-N tdiq Chemical compound C1CNCC2=C1C=C1OCOC1=C2 JHLDJOBIUVJSTG-UHFFFAOYSA-N 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 208000014001 urinary system disease Diseases 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 208000005647 Mumps Diseases 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 208000010805 mumps infectious disease Diseases 0.000 claims description 3
- 230000000626 neurodegenerative effect Effects 0.000 claims description 3
- 239000008184 oral solid dosage form Substances 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 229940100692 oral suspension Drugs 0.000 claims description 3
- 201000008152 organic acidemia Diseases 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 230000001568 sexual effect Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 102000011690 Adiponectin Human genes 0.000 claims description 2
- 108010076365 Adiponectin Proteins 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 48
- 208000012661 Dyskinesia Diseases 0.000 claims 4
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 208000010641 Tooth disease Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- WNFKUKXGPHQDKU-UHFFFAOYSA-N 3-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound OC(C)C=1C=CC(=NC=1)CCOC1=CC=C(CN2C(SCC2=O)=O)C=C1 WNFKUKXGPHQDKU-UHFFFAOYSA-N 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 206010036049 Polycystic ovaries Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 150000007524 organic acids Chemical group 0.000 claims 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 4
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 4
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000007827 neuronopathy Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382402 | 2018-06-06 | ||
| EP18382402.8 | 2018-06-06 | ||
| PCT/IB2019/054744 WO2019234690A1 (en) | 2018-06-06 | 2019-06-06 | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021527061A JP2021527061A (ja) | 2021-10-11 |
| JPWO2019234690A5 true JPWO2019234690A5 (https=) | 2022-06-14 |
| JP2021527061A5 JP2021527061A5 (https=) | 2022-06-14 |
| JP7510170B2 JP7510170B2 (ja) | 2024-07-03 |
Family
ID=62716011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567972A Active JP7510170B2 (ja) | 2018-06-06 | 2019-06-06 | ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210228558A1 (https=) |
| EP (1) | EP3801517A1 (https=) |
| JP (1) | JP7510170B2 (https=) |
| KR (1) | KR20210031867A (https=) |
| CN (1) | CN112823004A (https=) |
| AU (1) | AU2019283650A1 (https=) |
| BR (1) | BR112020024939A2 (https=) |
| CA (1) | CA3102584A1 (https=) |
| CL (1) | CL2020003163A1 (https=) |
| EA (1) | EA202092954A1 (https=) |
| IL (1) | IL279186A (https=) |
| MX (1) | MX2020013182A (https=) |
| SG (1) | SG11202012095XA (https=) |
| WO (1) | WO2019234690A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| FI3801515T3 (fi) | 2018-06-06 | 2025-05-27 | Minoryx Therapeutics S L | 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa |
| EP4142720A1 (en) * | 2020-04-30 | 2023-03-08 | Minoryx Therapeutics S.L. | Leriglitazone for treating lung inflammation and interstitial lung disease |
| CN117769418A (zh) * | 2021-05-19 | 2024-03-26 | 爱博利瓦有限公司 | Kl1333用于医疗 |
| MX2025013233A (es) * | 2023-05-09 | 2026-02-03 | Minoryx Therapeutics S L | Formas polimorficas y formulaciones de leriglitazona |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0639229B2 (en) | 1992-04-30 | 2009-11-25 | Institut Pasteur | Rapid detection of antibiotic resistance in mycobacterium tuberculosis |
| GB0030845D0 (en) * | 2000-12-18 | 2001-01-31 | Smithkline Beecham Plc | Novel treatment |
| GB0510469D0 (en) * | 2005-05-23 | 2005-06-29 | Leuven K U Res & Dev | Insulin sensitization to slow down pubertal tempo and to augment pubertal growth |
| AU2012203941A1 (en) * | 2006-06-27 | 2012-07-26 | Sandoz Ag | New method for salt preparation |
| WO2008000418A2 (en) * | 2006-06-27 | 2008-01-03 | Sandoz Ag | New method for salt preparation |
| WO2013040419A1 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| CA2941562C (en) | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| EP3125888B1 (en) | 2014-04-02 | 2018-05-23 | Minoryx Therapeutics S.L. | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| WO2017083739A1 (en) * | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to valproic acid therapy |
| EP3559010B1 (en) | 2016-12-23 | 2022-06-08 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
-
2019
- 2019-06-06 EA EA202092954A patent/EA202092954A1/ru unknown
- 2019-06-06 SG SG11202012095XA patent/SG11202012095XA/en unknown
- 2019-06-06 BR BR112020024939-4A patent/BR112020024939A2/pt not_active Application Discontinuation
- 2019-06-06 US US16/972,366 patent/US20210228558A1/en not_active Abandoned
- 2019-06-06 CN CN201980046666.1A patent/CN112823004A/zh active Pending
- 2019-06-06 WO PCT/IB2019/054744 patent/WO2019234690A1/en not_active Ceased
- 2019-06-06 EP EP19742913.7A patent/EP3801517A1/en active Pending
- 2019-06-06 MX MX2020013182A patent/MX2020013182A/es unknown
- 2019-06-06 AU AU2019283650A patent/AU2019283650A1/en not_active Abandoned
- 2019-06-06 JP JP2020567972A patent/JP7510170B2/ja active Active
- 2019-06-06 CA CA3102584A patent/CA3102584A1/en active Pending
- 2019-06-06 KR KR1020207037942A patent/KR20210031867A/ko not_active Abandoned
-
2020
- 2020-12-03 IL IL279186A patent/IL279186A/en unknown
- 2020-12-04 CL CL2020003163A patent/CL2020003163A1/es unknown
-
2023
- 2023-09-01 US US18/460,197 patent/US20240091210A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527061A5 (https=) | ||
| JP7615061B2 (ja) | 特発性肺線維症を治療する方法 | |
| CN117285590A (zh) | 一种化合物、其制备方法、包括其的组合物及其应用 | |
| EP4309738A2 (en) | Method of treating medulloblastoma with an ezh2 inhibitor | |
| JP2017511339A5 (https=) | ||
| JP2021527045A5 (https=) | ||
| JP7645797B2 (ja) | 有機化合物 | |
| JP7510170B2 (ja) | ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用 | |
| US20180305396A1 (en) | Deuterated compounds | |
| JPWO2019234690A5 (https=) | ||
| JP7549344B2 (ja) | 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法 | |
| EP3675845B1 (en) | Novel gamma aminobutyric acid type a receptor modulators for mood disorders | |
| JPWO2019234689A5 (https=) | ||
| JP6173352B2 (ja) | 筋萎縮性側索硬化症の治療方法 | |
| EP4471024A1 (en) | M-choline receptor agonist compound, preparation method therefor and use thereof | |
| CN112888436A (zh) | Tca循环中间体和其使用方法 | |
| WO2024245371A1 (zh) | 一种组合产品、盐及其用于治疗神经退行性疾病或病症的用途 | |
| CN111670041A (zh) | 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合 | |
| WO2026012320A1 (zh) | Ripk1抑制剂在预防和治疗血管损伤和糖尿病中的用途 | |
| WO2025224600A1 (en) | Treatment of alpha-synucleinopathies and neuroprotection | |
| WO2024095962A1 (ja) | Ｔｒｐｖ１アンタゴニストであるピリジン誘導体の使用 | |
| JP2024058212A (ja) | 自閉スペクトラム症治療のためのａｍｇ５１７の使用 | |
| US20220024976A1 (en) | Salt and crystalline forms of rapastinel | |
| EA047194B1 (ru) | Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей | |
| EA047277B1 (ru) | Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона |